Why the study?
Risks and benefits of intravenous rt-PA remain unclear among elderly patients with acute ischaemic stroke.
Does intravenous rt-PA improve 1-year functional outcomes (mRS 0-1) in Chinese patients aged >80 years with acute ischaemic stroke?
Does intravenous rt-PA improve 1-year functional outcomes (mRS 0-1) in Chinese patients aged >80 years with acute ischaemic stroke?
Intravenous rt-PA administered within 4.5 hours of symptom onset is associated with improved 1-year functional outcomes without increasing intracranial hemorrhage or mortality in Chinese patients over 80 years old with acute ischemic stroke.
Answers are grounded in this paper and cite their sources.
May support IV rt-PA in elderly Chinese AIS patients; extends observational data but leaves open need for RCTs.
Background Risks and benefits of intravenous recombinant tissue plasminogen activator (rt-PA) remain unclear among elderly patients with acute ischaemic stroke (AIS). This study investigated 1-year clinical outcomes of intravenous rt-PA treatment in Chinese patients aged >80 years with AIS. Methods This retrospective multicentre study included patients with AIS aged >80 years from the Computer-based Online Database of Acute Stroke Patients for Stroke Management Quality Evaluation stroke registry platform between January 2017 and March 2020 who arrived at the hospital within 4.5 hours of symptom onset. Patients who received intravenous rt-PA were propensity score-matched (1:1) by baseline characteristics with those who did not receive reperfusion therapy. The primary outcome was modified Rankin scale (mRS) score 0–1 at 1 year; secondary outcomes were any intracranial haemorrhage (ICH) and all-cause mortality during hospitalisation, mRS 0–2, mRS score distribution and all-cause mortality at 1 year. Results The analysis included 1560 propensity score-matched elderly patients (intravenous rt-PA, n=780; non-reperfusion, n=780). At 1 year, the intravenous rt-PA group had a higher proportion of patients with mRS 0–1 (27.7% vs 23.8%; OR 1.87, 95% CI 1.35 to 2.59, p<0.001), mRS 0–2 (37.3% vs 33.7%; OR 2.02, 95% CI 1.48 to 2.75, p < 0.001) and an overall shift towards better outcomes than placebo (mRS mean±SD score: 3.5±2.4 vs 3.7±2.3; OR 0.77, 95% CI 0.64 to 0.93, p=0.007). No significant differences were observed in any ICH and all-cause mortality during hospitalisation and at 1 year. Conclusions This study provided real-world evidence for a positive benefit-risk profile of intravenous rt-PA in Chinese patients with AIS aged >80 years. Trial registration number NCT05401149 .
No takes yet. Share an insight, caveat, or question.
Yang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: